Business Context and Reporting Period
Spruce Biosciences, Inc. (SPRB) is a late-stage biopharmaceutical company developing tildacerfont, a CRF1 receptor antagonist, for the treatment of classic congenital adrenal hyperplasia (CAH), polycystic ovary syndrome (PCOS), and major depressive disorder (MDD). This summary covers the quarterly period ended September 30, 2024 (Q3 2024), and the nine months ended September 30, 2024 (YTD 2024).
Key Financial Metrics
| Metric | Q3 2024 | Q3 2023 | YTD 2024 | YTD 2023 |
|---|---|---|---|---|
| Collaboration Revenue | $0.6 million | $3.1 million | $4.2 million | $7.2 million |
| Research & Development Expenses | $6.6 million | $13.5 million | $25.0 million | $38.3 million |
| General & Administrative Expenses | $3.5 million | $3.2 million | $11.3 million | $9.7 million |
| Net Loss | $(8.7) million | $(12.4) million | $(29.5) million | $(38.0) million |
| Cash and Cash Equivalents (Period End) | $60.1 million | $96.3 million (Dec 31, 2023) | $60.1 million | $96.3 million (Dec 31, 2023) |
| Accumulated Deficit | $(226.7) million | $(197.2) million (Dec 31, 2023) | $(226.7) million | $(197.2) million (Dec 31, 2023) |
| Term Loan Outstanding (Principal) | $2.2 million | $3.4 million (Dec 31, 2023) | $2.2 million | $3.4 million (Dec 31, 2023) |
Liquidity: The company reported a net cash used in operating activities of $35.3 million for the nine months ended September 30, 2024. Management believes current cash resources are sufficient to fund operations and debt obligations for at least 12 months following the filing date.
Material Changes vs. Prior Period
- Revenue Decline: Collaboration revenue decreased significantly due to the recognition schedule of the upfront payment from Kaken Pharmaceutical Co., Ltd. Revenue dropped from $3.1 million in Q3 2023 to $0.6 million in Q3 2024.
- Expense Reduction: Total operating expenses decreased by $6.7 million in Q3 2024 compared to Q3 2023. This was primarily driven by a $6.9 million reduction in R&D expenses, attributed to the termination of the CAHmelia-203 study, completion of the POWER study, and a reduction in headcount (approximately 21% in March 2024).
- Improved Net Loss: The net loss narrowed to $8.7 million in Q3 2024 from $12.4 million in Q3 2023, reflecting the significant decrease in operating expenses.
- Cash Position: Cash and cash equivalents decreased from $96.3 million at year-end 2023 to $60.1 million at September 30, 2024, primarily due to operating cash burn.
Outlook, Risks, and Management Commentary
Clinical Development Updates
- CAHmelia-203 (Adult CAH): The Phase 2b trial was terminated in March 2024 after failing to meet its primary efficacy endpoint. The company initiated CAHmelia-204, a second Phase 2b trial with a differentiated patient population, with topline results expected in December 2024.
- CAHptain-205 (Pediatric CAH): The Phase 2 trial met efficacy endpoints, though activity was less consistent than anticipated. The trial was amended to include additional dose-ranging cohorts, with results also expected in December 2024.
- PCOS: The POWER Phase 2 proof-of-concept study showed significant reduction in adrenal androgens (DHEAS) and increase in SHBG. The company is evaluating strategic collaboration opportunities for PCOS.
- MDD: In May 2024, the company entered an agreement with HMNC Holding GmbH to fund a Phase 2 proof-of-concept study of tildacerfont in MDD patients.
Risks and Contingencies
- Capital Requirements: The company anticipates needing substantial additional financing to continue clinical development and commercialization. Failure to secure funding could force delays or elimination of programs.
- Nasdaq Listing: The company received notice from Nasdaq regarding its stock price falling below $1.00. It has transferred listing to the Nasdaq Capital Market and received an extended compliance period until April 21, 2025, to regain compliance, potentially via a reverse stock split.
- Single Product Dependence: The business depends entirely on the success of tildacerfont. Failure in ongoing trials (CAHmelia-204, CAHptain-205) would materially harm the company.
- Debt Covenants: The company has a term loan with Silicon Valley Bank secured by substantially all assets (excluding IP). Default could lead to acceleration of debt and foreclosure.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $60.1 million cash balance against the projected burn rate, especially given the need for additional financing.
- Upcoming Data Readouts: Monitor the December 2024 topline results for CAHmelia-204 and CAHptain-205, which are critical for the company's survival and valuation.
- Nasdaq Compliance: Track the stock price to ensure it meets the $1.00 bid price requirement for 10 consecutive days before April 21, 2025, to avoid delisting.
- Collaboration Revenue: Assess the timeline for recognizing remaining deferred revenue from the Kaken agreement and potential new revenue from the HMNC agreement.
- Debt Obligations: Review the repayment schedule for the $2.2 million term loan maturing in January 2026 and ensure compliance with covenants.